Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethacrynic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 15/20 | 0.76 |
| ▸ | GSTA1 | P08263 | 9/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.76 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.76 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.76 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.76 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethacrynic Acid SCHEMBL18263238 | 0.95 | GSTP1 (0.86) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| SCHEMBL9717571 | 0.87 | GSTP1 (0.65) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| SCHEMBL10031684 | 0.86 | GSTP1 (0.80) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| Ethacrynic Acid SCHEMBL26353 | 0.86 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| SCHEMBL10014667 | 0.86 | GSTP1 (0.80) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| Ethacrynic Acid SCHEMBL9108011 | 0.86 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| SCHEMBL3713736 | 0.86 | GSTP1 (0.80) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| Ethacrynic Acid SCHEMBL29384243 | 0.86 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| Ethacrynic Acid SCHEMBL905726 | 0.85 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9MEN1ABCC3 | |
| Ethacrynic Acid SCHEMBL2482896 | 0.85 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299401-A1 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION | 2024-09-12 | — | — | US | claimed |
| WO-2024184378-A1 | FILM COATING FOR COLON TARGETING | UNIVERSITE DE LILLE (FR) | 2024-09-12 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022076611-A1 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-04-14 | — | — | WO | claimed |
| US-20210198741-A1 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | 10X GENOMICS, INC. | 2021-07-01 | — | — | US | claimed |
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2018-10-04 | — | — | US | claimed |
| US-10082498-B2 | Methods for treating ADHD and bipolar disorder using a membrane potential ratio test | PSYCHNOSTICS, LLC (US) | 2018-09-25 | — | — | US | claimed |
| EP-3368158-A1 | METHOD OF TREATMENT FOR THIRD SPACING | Webb, Robin L. (US) | 2018-09-05 | — | — | EP | claimed |
| US-10016379-B2 | Method of treatment for third spacing | WEBB ROBIN L (US) | 2018-07-10 | — | — | US | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0032725-B1 | NOVEL ALDEHYDE ADDUCTS OF TRIAMTERENE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1985-05-08 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0107095-A1 | 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents | MERCK & CO. INC. (US) | 1984-05-02 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299401-A1 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | SLC7A11, SLC39A11, GPX1 | GSTP1 243/4885GSTA1 134/4885CYP2C9 2484/4885 |
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | GSTP1 3038/4885GSTA1 3894/4885CYP2C9 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.